|
**
Denotes trials that will have an ACC News Conference
SUNDAY,
MARCH 18, 2001
Late-Breaking
Trials in Interventional Cardiology (#22), Hall E
Co-chairs: Spencer B. King, III, MD, and Eric J. Topol,
MD
8:45
a.m.
**Restenosis Intra-Stent:
Balloon Angioplasty vs. Elective Stenting: Results of
a Randomized Trial—Fernando Alfonso, MD, of
Madrid, Spain
8:58
a.m.
**The Beta-Cath System
Trial—Richard E. Kuntz, MD, of Boston
9:10
a.m.
Direct Myocardial Laser
Revascularization Using Biosense Left Ventricular Electromechanical
Mapping: Final Results of the DIRECT Randomized Trial—Martin
B. Leon, MD, of New York City
9:22
a.m.
**The Stent or Surgery
Trial (SoS)—Rodney Stables, MD, of Liverpool,
United Kingdom
9:34
a.m.
**The Medicine, Angioplasty,
or Surgery Study (MASS II): A Randomized, Controlled
Clinical Trial of Medical Therapy, Coronary Angioplasty,
or Bypass Surgery for Multivessel Coronary Artery Disease—Whady
Hueb, MD, of Sao Paulo, Brazil
9:46
a.m.
**The Washington Radiation
for In-Stent Restenosis Trial for Saphenous Vein Grafts
(SVG WRIST)—Ron Waksman, MD, of Washington,
D.C.
SUNDAY,
MARCH 18, 2001
Arrhythmia/Device
Trial Update (#61), Hall A3
Co-chairs: Gerald V. Naccarelli, MD, and Mark H. Schoenfeld,
MD
8:00
a.m.
Prophylactic Use of Implantable
Cardioverter Defibrillators in Patients With Idiopathic
Dilated Cardiomyopathy: The Cardiomyopathy Pilot Trial
(CAT)—Seven-Year Follow-up—Karl-Heinz
Kuck, MD, of Hamburg, Germany
8:25
a.m.
Update on Pacing Trials—Gervasio A. Lamas, MD,
of Miami Lakes, Fla.
8:50
a.m.
Sudden Cardiac Death: Primary and Secondary Prevention
Trial Update—David S. Cannom, MD, of Los Angeles
9:15
a.m.
**Dual-Site Atrial
Pacing for Prevention of Atrial Fibrillation Trial (DAPPAF)—Sanjeev
Saksena, MD, of Millburn, N.J.
9:40
a.m.
Update on Atrial Fibrillation Trials—D. George
Wyse, MD, of Calgary, Canada
MONDAY,
MARCH 19, 2001
Late-Breaking
Clinical Trials I (#405), Hall E
Co-chairs: Jeffrey L. Anderson, MD, and Sanjiv Kaul,
MD
9:15
a.m.
Aggressive Diagnosis
of Restenosis (ADORE) Trial—Mark J. Eisenberg,
MD, of Montreal, Canada
9:30
a.m.
**Adenovirus FGF Angiogenic
Gene Therapy (AGENT) Trial for Stable Angina—Cindy
L. Grines, MD, of Royal Oak, Mich.
9:45
a.m.
**Therapeutic Angiogenesis
With Recombinant Fibroblast Growth Factor-2 for Intermittent
Claudication (TRAFFIC): Results After 180 Days—Robert
J. Lederman, MD, of Bethesda, Md.
10:00
a.m.
A Placebo-Controlled
Safety and Pharmacology Study of ALT-711 in Older Patients
With Stiffened Cardiovasculature—David A. Kass,
MD, of Baltimore, Md.
10:15
a.m.
**Clopidogrel in Unstable
Angina to Prevent Recurrent Ischemic Events (CURE)—Salim
Yusuf, MD, of Ontario, Canada
TUESDAY,
MARCH 20, 2001
Late-Breaking
Clinical Trials II (#414), Hall E
Co-chairs: Barry M. Massie, MD, and John M. Miller,
MD
8:30
a.m.
Mortality and Stroke
Rates in a Trial of Rhythm Control vs. Rate Control
in Atrial Fibrillation: Results from the STAF Pilot
Phase (Strategies of Treatment of Atrial Fibrillation)—Joerg
Carlsson, MD, Detmold, Germany
8:45
a.m.
**Multicenter InSync
Randomized Clinical Evaluation (MIRACLE): Results of
a Randomized, Double-Blind, Controlled Trial to Assess
Cardiac Resynchronization Therapy in Heart Failure Patients—William
T. Abraham, MD, of Lexington, Ky.
9:00
a.m.
**Carvedilol Prospective
Randomized Cumulative Survival Trial (COPERNICUS)—Milton
Packer, MD, of New York City
9:15
a.m.
**Carvedilol Post-Infarct
Survival Control in Left Ventricular Dysfunction (CAPRICORN)—Henry
J. Dargie, MD, of Glasgow, United Kingdom
9:30
a.m.
**Prospective, Randomized,
Double-Blind, Placebo-Controlled, Multicenter Study
of the Efficacy and Safety of Tezosentan in Patients
With Acute Decompensated Heart Failure (RITZ-2)—Guillermo
Torre-Amione, MD, of Houston
9:45
a.m.
Better Long-Term
Clinical and Angiographic Results After Stent Placement
for Long Coronary Artery Stenoses Guided by Intravascular
Ultrasound Compared to Angiography: Results of a Randomized
Study—Pranobe Oemrawsingh, MD, of Leiden, the
Netherlands
WEDNESDAY,
MARCH 21, 2001
Late-Breaking
Clinical Trials III (#423), Hall E
Co-chairs: Joseph E. Parrillo, MD, and Eric S. Williams,
MD
8:30
a.m.
**Multiple Outcomes
of Raloxifene Evaluation (MORE)—Elizabeth Barrett-Connor,
MD, of La Jolla, Calif.
8:45
a.m.
Improved Reperfusion
and Clinical Outcome With Enoxaparin as an Adjunct to
Streptokinase Trombolysis in Acute Myocardial Infarction
(AMI-SK)—Angeles Alonso, MD, Madrid, Spain
9:00
a.m.
**The Pravastatin
Inflammation/CRP Evaluation (PRINCE)—Paul M.
Ridker, MD, of Boston
9:15
a.m.
**Treat Angina
With Aggrastat and Determine Cost of Therapy With an
Invasive or Conservative Strategy (TACTICS)-TIMI 18—William
S. Weintraub, MD, of Atlanta
9:30
a.m.
**Program to Assess
Alternative Treatment Strategies to Achieve Cardiac
Health (PATCH): EDTA Study—D. George Wyse,
MD, of Calgary, Canada
9:45
a.m.
Effects of Enrasentan,
a Nonselective Endothelin Receptor Angagonist, in Class
II-III Heart Failure: Results of the ENCOR Trial—William
T. Abraham, MD, of Lexington, Ky.
|
